Hansa Biopharma AB HNSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 27.32
- Day Range
- SEK 26.70–29.00
- 52-Week Range
- SEK 20.14–58.10
- Bid/Ask
- SEK 28.80 / SEK 28.92
- Market Cap
- SEK 1.52 Bil
- Volume/Avg
- 117,673 / 141,004
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 166
- Website
- https://www.hansabiopharma.com
Comparables
Valuation
|
Metric
|
HNSA
|
CALTX
|
SYNACT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 16.62 | 1.35 |
Price/Sales | 8.66 | 4.61 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HNSA
|
CALTX
|
SYNACT
|
|---|---|---|---|
Quick Ratio | 2.57 | 2.85 | 3.00 |
Current Ratio | 2.66 | 3.13 | 3.01 |
Interest Coverage | −7.14 | −5.64 | −281.14 |
Quick Ratio
HNSA
CALTX
SYNACT
Profitability
|
Metric
|
HNSA
|
CALTX
|
SYNACT
|
|---|---|---|---|
Return on Assets (Normalized) | −71.82% | −24.68% | −52.48% |
Return on Equity (Normalized) | — | −89.92% | −64.95% |
Return on Invested Capital (Normalized) | −85.22% | −31.14% | −64.46% |
Return on Assets
HNSA
CALTX
SYNACT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rkcgyntkg | Mmv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qzzzknr | Sgywlk | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Flhpzgns | Kmzrgns | $97.8 Bil | |
MRNA
| Moderna Inc | Twdpmct | Dwy | $41.3 Bil | |
ARGX
| argenx SE ADR | Fxvtmrcp | Ndthd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hcrxfvkq | Gynv | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hjxnrfnj | Flxglt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zrfxcptpn | Nznxhd | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hpzjslxwh | Wbgxx | $12.5 Bil | |
INCY
| Incyte Corp | Mkcvcktp | Wbmbbs | $11.6 Bil |